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dRIEF REPORT
he Effects of Methylphenidate on DecisionMaking in
ttention-Deficit/Hyperactivity Disorder
lise E. DeVito, Andrew D. Blackwell, Lindsey Kent, Karen D. Ersche, Luke Clark, Claire H. Salmond,
nna Maria Dezsery, and Barbara J. Sahakian
ackground: Children with attention-deficit/hyperactivity disorder (ADHD) frequently display poor judgment and risk taking in their
veryday behavior, but there are little empirical data on decision-making cognition in this disorder. The objectives of the study were to
ssess the effects of stimulantmedication ondecisionmaking inADHDand compare performance on theCambridgeGamble Task between
oys with and without ADHD.
ethods: Twenty-one boys (aged 7–13) diagnosed with ADHD underwent a double-blind, placebo-controlled trial of methylphenidate
.5 mg/kg) during which they performed the Cambridge Gamble Task (CGT). A healthy age-matched control group was tested on two
ccasions off drug.
esults: The ADHD group bet more conservatively on the methylphenidate session than on the placebo session. In comparison with healthy
ontrol subjects, the ADHD group made more poor decisions, placed their bets more impulsively, and adjusted their bets less according to the
hances of winning. Poor decisionmakingwas correlatedwith parent-reported symptoms and disruptive behavior in the ADHDgroup.
onclusions: Methylphenidate reduced risk-prone betting behavior on the CGT. Compared with control subjects, children with ADHD
isplay a number of decision-making deficits on the task, and the measure of rational decision making may serve as an ecologically valid
europsychological marker of impairment.ey Words: Attention-deficit/hyperactivity disorder (ADHD), Cam-
ridge Gamble Task (CGT), decisionmaking,methylphenidate (MPH)
ttention-deficit/hyperactivity disorder (ADHD), a preva-
lent psychiatric disorder characterized by hyperactivity,
impulsivity, and inattention, is diagnosed by pervasive
aladaptive behaviors during childhood (1). Children with
DHD display a range of cognitive impairments on laboratory
asks and risk-taking behaviors in daily life. Previous neuropsy-
hological studies have investigated the mechanisms underlying
DHD behavior in terms of disinhibition, delay aversion, and
bnormal reward sensitivity (2). However, few studies have
ssessed affective decision making. Iowa Gambling Task (IGT)
indings are inconsistent in ADHD, possibly reflecting task
ensitivity to disrupted working memory and learning (3,4).
Pharmacotherapy with methylphenidate (MPH) improves be-
avioral symptoms and cognitive function (e.g., attention, inhi-
ition, working memory) in ADHD (5), producing similar effects
n animals and healthy humans (6). Methylphenidate inhibits
opamine and noradrenaline reuptake, primarily in the prefron-
al cortex (PFC) (6) and may compensate for frontostriatal
athophysiology in ADHD. The effect of MPH treatment on
ecision-making cognition in ADHD is not known, although
mpulsive and risk-taking behaviors are important aspects of
DHD symptomatology. We investigated methylphenidate’s im-
act on decision making in childhood ADHD, using the Cam-
ridge Gamble Task (CGT). Cambridge Gamble Task measures
ecision making and risk taking through betting behavior. The
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oi:10.1016/j.biopsych.2008.04.017CGT was devised to minimize working memory and learning
components by presenting outcome probabilities explicitly (7).
Neural circuitry implicated in emotional decision making contin-
ues to develop through adolescence (8), so children may per-
form CGT differently than adults. As this is the first study to
employ the CGT in this age group, we included a group of
healthy boys matched for demographic variables to detect deci-
sion-making cognition abnormalities in ADHD. The relationship
between CGT performance and behavioral ratings was assessed
to determine the task’s ecological validity.
Methods andMaterials
Parental written informed consent and ethics committee
approval were obtained.
Psychiatrists referred consecutive attendees to a childhood
ADHD outpatient clinic. Diagnoses following DSM-IV guidelines
including pervasiveness of symptoms (1) were established with
3-hour clinical assessments based on the Schedule for Affective
Disorders and Schizophrenia for School-Age Children (K-SADS),
developmental and family histories, and teacher reports. Attention-
deficit/hyperactivity disorder patients (n  21) were males, aged 7
to 13, and stabilized on methylphenidate with no primary learning
disabilities or concomitant neurological, psychiatric, or behavioral
disorders (except history of oppositional defiant disorder; n  14).
A healthy control group (HC) (n  22; aged 7 to 12) was recruited
with posters from the local community.
The ADHD boys underwent a double-blind, placebo-con-
trolled, crossover design of a single .5 mg/kg dose of methyl-
phenidate or placebo. One child received .25 mg/kg (10 mg) due
to his high weight and low therapeutic dose. Participants ab-
stained from MPH for 21 to 28 hours (approximately 5 to 7
half-lives) prior to testing sessions. Methylphenidate reaches
peak plasma concentration in approximately 2 hours (9). Ques-
tionnaires were completed once at the start of a visit to avoid
treatment effects. Cambridge Gamble Task testing began at least
1.75 hours after pills were ingested. Healthy control subjects
attended two sessions but received no pills.
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ive symptoms. Parents completed disruptive behavior question-
aires (Achenbach Child Behavior Checklist [11]; Conners Symp-
om Behavior Checklist [12]) based on their son’s behavior
ithout medication. The ADHD group completed Visual Ana-
ogue Scales (VAS) (13) modified with age-appropriate vocabu-
ary prior to pills (t0), prior to cognitive testing (t1), and after
esting (t2).
The Cambridge Gamble Task (Cambridge Neuropsychologi-
al Test Automated Battery [CANTAB]; www.camcog.com) (7)
ssessed decision making under risk. On each trial, participants
ere presented with an array of 10 boxes, colored red or blue.
he ratio of colored boxes varied across trials. On each trial, the
articipant was asked to guess which color concealed a token,
hen wager a proportion of his total points on his color decision.
agers were offered in ascending (5%, 25%, 50%, 75%, 95% of
urrent points) or descending (95%, 75%, 50%, 25%, 5% of
urrent points) sequences presented for 2.5 seconds each. After
he bet was placed, the hidden token was revealed and the bet
as added to or subtracted from the running score. “Ratio-
al choices” is the proportion of trials where the majority color
as chosen. “Deliberation time” is the latency to make the color
hoice. “Amount bet” is averaged across conditions and box
igure 1. Methylphenidate reduces the amount bet by ADHD group with-
ut ameliorating risk adjustment deficits relative to control subjects. Bets
re displayed as an average of the percentage of total points wagered on
ach decision. ADHD, attention-deficit/hyperactivity disorder; MPH, meth-
lphenidate.
able 1. Cambridge Gamble Task Key Measures
GT Measures HCa,b ADHD-
ational Choices .93  .02, (.90, .94) .80
eliberation Time 2517  390, (2611, 2424) 3203
mount Bet 66.67  2.10, (65.85, 69.68) 69.80
mpulsivity Index 18.34 3.05, (26.10, 18.35) 31.44
isk Adjustment 1.48 .19, (1.37, 1.59) .44
ADHD, attention-deficit/hyperactivity disorder; ADHA-MPH, ADHD gro
C, healthy control; MPH, methylphenidate; SEM, standard error of the mea
aMeans standard error of the mean (SEM) are presented for Cambridg
msec), amount bet, impulsivity index, and risk adjustment.
bHealthy control (HC) data are averaged across both visits. Means for ea
cGroupeffect notes thedifferences andeffect sizes [F (p),d] between the
ovaried for age.
dDrug effect describes significant differences and effect sizes [F (p), d] b
roup with a between-subject factor of drug/placebo visit order.
eStatistically significant p values.ratios. Higher bets are assumed to indicate risk preference.
“Impulsivity index” is the difference in percentage bet in de-
scending versus ascending conditions. Consistently early bets
(e.g., 95% points descending  5% points ascending) produce a
high impulsivity index. “Risk adjustment index” quantifies bet
calibration across ratios {[2*(% bet 9:1)  (% bet 8:2)  (% bet
7:3)  2*(% bet 6:4)]/Average % bet}, so higher scores are
preferable (14).
Repeated-measures analysis of variance (ANOVA), with be-
tween-subject factors of methylphenidate/placebo order, com-
pared the ADHD group on placebo (ADHD-P) versus methyl-
phenidate (ADHD-MPH) on CGT measures and change in VAS
factors (t1 t2 t0) (13). Deliberation times were logarithmically
transformed; rational choices were arcsine transformed (14) to
decrease skew and stabilize variances. Groups were compared
on demographic variables with t tests and chi-squared analysis.
Univariate analysis of covariance (ANCOVA), covaried for age,
examined ADHD-P versus HC performance on all CGT measures
and ADHD-MPH versus HC for measures that significantly re-
sponded to drug manipulation. Healthy control group data were
assessed for practice effects using repeated measures ANOVA
then averaged across visits, since ADHD-P visits were counter-
balanced. Effect sizes were calculated as d  (1 2)/[(1
2 
2
2)/2] (15). The relationship between CGT measures and behav-
ioral ratings (ConnersTotal, AchenbachTotal, AchenbachInternalizing,
AchenbachExternalizing) were determined using Pearson’s prod-
uct-moment correlation coefficient. Other summary question-
naire measures were not analyzed.
Results
Attention-deficit/hyperactivity disorder and HC groups were
matched for age (t  .57, p  .571; meanADHD  10.00,
standard deviationADHD  2.05; meanHC  10.32, standard
deviationHC  1.59), test order (t  .45, p  .659), days
between visits (t  .71, p  .482), years of education (t 
1.06, p .297), and distribution of younger (7–10) versus older
(11–13) children (df  1, X2  1.13, p  .29). The ADHD group
had higher disruptive behavior ratings (AchenbachTotal t  6.80,
p  .001; AchenbachInternalizing t  4.73, p  .001; AchenbachExter-
nalizingt  6.79, p  .001; ConnersTotal t  9.06, p  .001) and a
trend toward higher depressive symptoms (t  1.88; p  .068).
The HC group showed no significant practice effects on the CGT
(F  1.43–2.63, p  .13–.25, d  .19–.49).
On methylphenidate, the ADHD group bet significantly fewer
ADHD-MPHa Group Effectc Drug Effectd
.81  .04 10.65 (.002)e, .98 .00 (.989), .03
2778  253 1.25 (.273), .44 .96 (.342), .28
60.50  2.91 .66 (.422), .27 8.54 (.010)e, .68
33.25  5.76 4.44 (.042)e, .67 .14 (.717), .13
.54  .21 11.38 (.002)e, .93 .37 (.551), .10
MPH; ADHD-P, ADHD group on placebo; CGT, Cambridge Gamble Task;
ble Task (CGT) measures; proportion of rational choices, deliberation time
it are also provided (meanHCvisit1, meanHCvisit2).
y control data averaged across both visits and theADHDgrouponplacebo,
en the drug (ADHD-MPH) and placebo (ADHD-P) conditions in the ADHDPa
.04
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woints than on placebo (Figure 1) but did not differ on other CGT
easures (Table 1). Methylphenidate did not have a significant
ain effect on VAS factors (calmness: F  1.20, p  .291;
lertness: F  .60, p  .450; happiness: F  .33, p  .576).
articipants receiving methylphenidate at visit 1 reported feeling
almer than on placebo (Fdrug 	 visit  8.26, p  .012).
The ADHD-P group performed less optimally than HC on
ational choices across all box ratios, risk adjustment, and
mpulsivity index but did not differ on amount bet or deliberation
imes (Figure 1, Table 1). The ADHD-MPH and HC groups did
ot significantly differ on amount bet (F 2.96, p .09, d .53).
For ADHD-P, higher behavioral ratings were associated with
oor quality of decision making (ConnersTotal r18 .673, p 
002; AchenbachTotal r18 .670, p  .002; AchenbachInternalizing
18 .506, p  .038; AchenbachExternalizing r18 .545, p 
024) (Figure 2). For HC, Achenbach correlated with impulsivity
ndex (AchenbachTotal r19 .545, p .016; AchenbachExternalizing
19  .701, p  .001). No other behavioral rating scores corre-
ated significantly with CGT performance (p  .195), although
ow variance on rating scales in control subjects may have limited
ur sensitivity to detect additional correlations.
iscussion
Methylphenidate significantly reduced CGT betting behavior
n children with ADHD without affecting performance on other
easures. These methylphenidate effects replicated findings in
rontal variant frontotemporal dementia (fvFTD) patients, where
PH reduced betting (16). The ventromedial prefrontal cortex
vmPFC) has been robustly linked to decision making: patients
ith vmPFC disruption (e.g., fvFTD) display elevated betting on
GT (3,16). It is conceivable that MPH modulates betting behav-
or via action on the neural network, including vmPFC, which
ubserves performance on CGT.
High CGT betting increases potential losses, therefore indi-
ating risk taking. Despite their abnormal pattern of betting, the
DHD group did not bet high amounts for all ratios. However,
ase-control comparisons indicated significant decision-making
mpairments in the ADHD group on other CGT variables. On
lacebo, the ADHD group bet more impulsively than control
ubjects, selecting high or low bets early in the bet sequence.
his shortens the task duration, consistent with ADHD perfor-
ance profiles on delayed reward tasks, indicating delay aver-
ion (17) or motor impulsivity. The ADHD-P group also made
ewer rational choices and risk adjusted less than healthy control
ubjects, yet both groups altered their bets according to the ratios
nd made rational choices at above-chance rates. The magnitude
f these deficits on rational choices was associated with higher
DHD symptom ratings. In this ADHD sample, CGT rational
hoices accounted for even more of the variance in behavioral
ymptoms than was accounted for by delayed choice or stop
ignal impulsivity in a previous study (17). Replication and
xtension of these findings in a larger ADHD sample size
ncluding female subjects would clarify their generalizability.
his measure of poor decision making was previously found to
orrelate with key clinical measures in other disorders associated
ith PFC abnormalities (e.g., 7).
Several factors may underpin the deficits in rational choices
nd risk adjustment. Children with ADHD modulate their behav-
or according to rates and magnitudes of gains and losses less
han their peers (4), who do so less than adults (18). The ability
o weigh competing factors to optimize decision making devel-
ps into adulthood (19). Therefore, poor risk adjustment in
ww.sobp.org/journalADHD could represent an exaggeration of a normal develop-
mental pattern (20).
Conclusions
Poor quality decision making was associated with ADHD
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Figure 2. Rational choices and behavioral ratings. Rational choices is the
average for the proportion of trials where the subject selected the box color
that was in the majority. ADHD, attention-deficit/hyperactivity disorder.behavioral symptoms. Methylphenidate induced conservative
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E.E. DeVito et al. BIOL PSYCHIATRY 2008;64:636–639 639etting behavior in childhood ADHD but did not ameliorate their
ecision-making deficits.
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